Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has shared an update.
CSL Limited has announced an update on its ongoing on-market buy-back program, with a total of 2,604,378 ordinary fully paid securities bought back before the previous day and an additional 29,882 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing its market position and demonstrating confidence in its financial health.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biopharmaceutical industry, focusing on the development and delivery of innovative medicines and therapies. The company is known for its work in immunology, hematology, and other specialty areas, serving a global market with a strong emphasis on research and development.
YTD Price Performance: -33.33%
Average Trading Volume: 1,175,192
Technical Sentiment Signal: Sell
Current Market Cap: A$89.32B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.